

1. A compound of formula I,



L is a divalent group selected from




Y is NR or S;

Z is CR or N;


R¹ is C₃₋₁₀ aryl which is optionally substituted with C₁₋₆ aliphatic, halogen or cyano;

R² is -CF₃,




2. The compound of claim 1, wherein A' is C=O, CH₂, CHOH, or NH.

3. The compound of Claim 1, wherein R^1 is




4. The compound of claim 1, of formula **I-a**,



I-a;

or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, of formula **I-c**,



I-c;

or a pharmaceutically acceptable salt thereof.


6. The compound of claim 1, of formula **I-e**,



I-e;

or a pharmaceutically acceptable salt thereof.


7. The compound of claim 1, of formula **I-h**,




I-h;

or a pharmaceutically acceptable salt thereof.


8. The compound of claim 1, selected from




1




2




3




4




5







6




7




8


**9****10****11****12**




13




14




15




16




17




18




19




20




21




22




23




24




25




26



27



28



and 29

9. A pharmaceutical composition comprising a compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

10. A pharmaceutical composition comprising the compound of any one of claims 1-8, or a pharmaceutical acceptable salt thereof, for use in treating an IRAK-mediated disorder in a patient in need thereof wherein the disorder is selected from Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, endometriosis; Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, and Cancer.

11. A pharmaceutical composition comprising compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need thereof.

12. The pharmaceutical composition of claim 10, wherein the IRAK-mediated disorder is selected from Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus nephritis, and Multiple Sclerosis.